Choose a language and wait for the translated text.
Shots:
Zealand Pharma has initiated the P-II (ZYNERGY) dose-finding trial of once-weekly petrelintide (amylin analog) co-administered with enicepatide (GLP-1/GIP receptor agonist) vs PBO, petrelintide monotherapy & enicepatide monotherapy in participants with obesity or overweight with ≥1 weight-related comorbidity
The trial, sponsored & conducted by Roche, will evaluate 3 dose regimens through wk 40 and is expected to enroll 480 participants; the 1EP is % change in body weight from baseline to wk 40, with 2EPs including change in waist circumference, HbA1c & cardiometabolic risk factors
ZYNERGY is designed to support dose selection for P-III. Zealand & Roche entered into an exclusive collaboration & licensing agreement in 2025 to co-develop & co-commercialize petrelintide
Ref: Globe Newswire | Image: Zealand Pharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Zealand Pharma Initiates the P-II (ZYNERGY) Trial of Petrelintide Co-Administered with Enicepatide for Obesity or Overweight appeared first on PharmaShots.
Zealand Pharma Initiates the P-II (ZYNERGY) Trial of Petrelintide Co-Administered with Enicepatide for Obesity or Overweight | PharmaVoice